<GlossaryTerm id="CDR0000648985"><TermName>DT2219ARL immunotoxin</TermName><TermPronunciation>(… IH-myoo-noh-TOK-sin)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of B-cell cancer. It contains an antibody linked to a toxic substance. The antibody binds to proteins called CD19 and CD22 on the surface of B cells, and the toxic substance kills the cells. It is a type of bispecific ligand-directed toxin.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000726401" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;DT2219ARL immunotoxin&quot;" language="en" id="_3"/><MediaLink ref="CDR0000726400" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inmunotoxina DT2219ARL&quot;" language="es" id="_4"/><SpanishTermName>inmunotoxina DT2219ARL</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamieno de ciertos tipos de cánceres de células B. Contiene un anticuerpo ligado a una sustancia tóxica. Los anticuerpos se adhieren las proteínas llamadas CD19 y CD22 en la superficie de las células B, y la sustancia tóxica elimina las células. Es un tipo de toxina biespecífica dirijida a los ligandos.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-11-13</DateFirstPublished></GlossaryTerm>
